Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma

Dabrafenib (Tafinlar, Novartis Pharmaceuticals) with trametinib (Mekinist, Novartis Pharmaceuticals) is indicated for 'the adjuvant treatment of adult patients with stage 3 melanoma with a BRAF V600 mutation, following complete resection'.

For dabrafenib, the recommended dose is 150 mg taken orally, twice daily. For trametinib, the recommended dose is 2 mg taken orally, once daily.

The list price for 28 capsules of dabrafenib 75 mg is £1,400 and for 30 tablets of trametinib 2 mg is £4,800 (company submission).

The company has a commercial arrangement for each drug. This makes dabrafenib with trametinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.